GenMark Diagnostics Inc (GNMK)

11.56
NASDAQ : Health Care
Prev Close 11.56
Day Low/High 0.00 / 0.00
52 Wk Low/High 4.20 / 11.98
Avg Volume 346.70K
Exchange NASDAQ
Shares Outstanding 42.99M
Market Cap 503.03M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

GenMark Diagnostics To Present At The 36th Annual Canaccord Genuity Growth Conference

GenMark Diagnostics To Present At The 36th Annual Canaccord Genuity Growth Conference

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the 36th...

GenMark Diagnostics Schedules Second Quarter 2016 Financial Results Conference Call For July 28, 2016

GenMark Diagnostics Schedules Second Quarter 2016 Financial Results Conference Call For July 28, 2016

GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its second quarter earnings results after market close on Thursday, July 28, 2016.

GenMark Achieves CE Mark For Its EPlex® Sample-to-Answer System

GenMark Achieves CE Mark For Its EPlex® Sample-to-Answer System

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has achieved CE Mark under the European In-Vitro Diagnostic Devices...

Insider Trading Alert - GNMK, CLRO And ADSK Traded By Insiders

Insider Trading Alert - GNMK, CLRO And ADSK Traded By Insiders

Stocks with insider trader activity include GNMK, CLRO and ADSK

GenMark Diagnostics To Present At The William Blair 36th Annual Growth Stock Conference

GenMark Diagnostics To Present At The William Blair 36th Annual Growth Stock Conference

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the...

Commit To Purchase GenMark Diagnostics At $7.50, Earn 31.2% Annualized Using Options

Commit To Purchase GenMark Diagnostics At $7.50, Earn 31.2% Annualized Using Options

Investors eyeing a purchase of GenMark Diagnostics, Inc. stock, but cautious about paying the going market price of $8.63/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Short Interest In GenMark Diagnostics Decreases By 11.2%

Short Interest In GenMark Diagnostics Decreases By 11.2%

The most recent short interest data has been released for the 04/29/2016 settlement date, which shows a 558,337 share decrease in total short interest for GenMark Diagnostics, Inc. , to 4,404,251, a decrease of 11.25% since 04/15/2016.

Insider Trading Alert - PTC, EVR And GNMK Traded By Insiders

Insider Trading Alert - PTC, EVR And GNMK Traded By Insiders

Stocks with insider trader activity include PTC, EVR and GNMK

GenMark Reports First Quarter 2016 Results

GenMark Reports First Quarter 2016 Results

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the first quarter ended March 31, 2016.

GenMark Diagnostics Schedules First Quarter 2016 Financial Results Conference Call For May 3, 2016

GenMark Diagnostics Schedules First Quarter 2016 Financial Results Conference Call For May 3, 2016

GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 3, 2016.

Insider Trading Alert - GNMK, NEWT And ETM Traded By Insiders

Insider Trading Alert - GNMK, NEWT And ETM Traded By Insiders

Stocks with insider trader activity include GNMK, NEWT and ETM

Insider Trading Alert - GNMK, LKQ And USNA Traded By Insiders

Insider Trading Alert - GNMK, LKQ And USNA Traded By Insiders

Stocks with insider trader activity include GNMK, LKQ and USNA

Insider Trading Alert - GNMK, DIN And COR Traded By Insiders

Insider Trading Alert - GNMK, DIN And COR Traded By Insiders

Stocks with insider trader activity include GNMK, DIN and COR

GenMark Diagnostics Enters Oversold Territory (GNMK)

GenMark Diagnostics Enters Oversold Territory (GNMK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

GenMark Reports Fourth Quarter And Full Year 2015 Results

GenMark Reports Fourth Quarter And Full Year 2015 Results

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2015.

GNMK: Insiders vs. Shorts

GNMK: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 01/29/2016 settlement date, and GenMark Diagnostics, Inc. is one of the most shorted stocks of the Russell 3000, based on 22.70 "days to cover" versus the median component at 4.92.

Insider Trading Alert - GNMK, ENSG And USNA Traded By Insiders

Insider Trading Alert - GNMK, ENSG And USNA Traded By Insiders

Stocks with insider trader activity include GNMK, ENSG and USNA

Relative Strength Alert For GenMark Diagnostics

Relative Strength Alert For GenMark Diagnostics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

GenMark Announces Preliminary Q4 Financial Results And Initiation Of EPlex™ Analytical Studies

GenMark Announces Preliminary Q4 Financial Results And Initiation Of EPlex™ Analytical Studies

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported preliminary fourth quarter 2015 results.

GenMark Diagnostics To Present At The 2016 J.P. Morgan Healthcare Conference

GenMark Diagnostics To Present At The 2016 J.P. Morgan Healthcare Conference

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 2016 J.

Commit To Purchase GenMark Diagnostics At $7.50, Earn 18.4% Annualized Using Options

Commit To Purchase GenMark Diagnostics At $7.50, Earn 18.4% Annualized Using Options

Investors eyeing a purchase of GenMark Diagnostics, Inc. shares, but tentative about paying the going market price of $7.89/share, might benefit from considering selling puts among the alternative strategies at their disposal.

GNMK: Insiders vs. Shorts

GNMK: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 10/30/2015 settlement date, and GenMark Diagnostics, Inc. is one of the most shorted stocks of the Russell 3000, based on 6.94 "days to cover" versus the median component at 5.62.

Insider Trading Alert - GNMK, FN And CRM Traded By Insiders

Insider Trading Alert - GNMK, FN And CRM Traded By Insiders

Stocks with insider trader activity include GNMK, FN and CRM

Insider Trading Alert - NWBI, GNMK And FTK Traded By Insiders

Insider Trading Alert - NWBI, GNMK And FTK Traded By Insiders

Stocks with insider trader activity include NWBI, GNMK and FTK

GenMark Diagnostics Reports Q3 Financial Results

GenMark Diagnostics Reports Q3 Financial Results

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported third quarter 2015 financial results.

GenMark Diagnostics is Now Oversold (GNMK)

GenMark Diagnostics is Now Oversold (GNMK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

GenMark Diagnostics Schedules Third Quarter 2015 Financial Results Conference Call For October 27, 2015

GenMark Diagnostics Schedules Third Quarter 2015 Financial Results Conference Call For October 27, 2015

GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Tuesday, October 27, 2015.

Oversold Conditions For GenMark Diagnostics (GNMK)

Oversold Conditions For GenMark Diagnostics (GNMK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.